PMID- 15746584
OWN - NLM
STAT- MEDLINE
DCOM- 20050705
LR  - 20190917
IS  - 0959-4973 (Print)
IS  - 0959-4973 (Linking)
VI  - 16
IP  - 4
DP  - 2005 Apr
TI  - Sustained complete remission of metastatic dermatofibrosarcoma protuberans with 
      imatinib mesylate.
PG  - 461-6
AB  - Dermatofibrosarcoma protuberans (DFSP) is a soft tissue tumor which may recur 
      locally and rarely causes metastases to vital organs. DFSPs have specific 
      chromosomal abnormalities involving the platelet-derived growth factor beta-chain 
      locus (PDGFB) which may render these tumors responsive to targeted therapy with 
      the tyrosine kinase inhibitor imatinib mesylate. A patient with locally recurrent 
      and metastatic DFSP resistant to first-line chemotherapy was treated with 
      imatinib mesylate 400 mg/day. The tumor was examined by a novel fluorescence in 
      situ hybridization (FISH) method for specific rearrangements of the PDGFB locus. 
      The patient was followed for response and toxicity by physical examination and 
      imaging studies. FISH revealed PDGFB rearrangement indicative of multiplication 
      of the PDGFB fusion locus within a ring chromosome. Physical examination showed 
      response within the first month of treatment, and subsequent computed tomography 
      and fluorodeoxyglycose positron emission tomography documented complete response 
      to imatinib therapy. Our patient is now in sustained complete remission for 20 
      months with minimal toxicity. We conclude that sustained complete remission of 
      metastatic DFSP with specific FISH abnormalities involving the PDGFB locus can be 
      obtained with imatinib mesylate with minimal toxicity for the patient.
FAU - Labropoulos, Stefanos V
AU  - Labropoulos SV
AD  - First Department of Medical Oncology, Hygeia Hospital, Marousi, Greece. 
      slabropoulos@yahoo.com
FAU - Fletcher, Jonathan A
AU  - Fletcher JA
FAU - Oliveira, Andre M
AU  - Oliveira AM
FAU - Papadopoulos, Savvas
AU  - Papadopoulos S
FAU - Razis, Evangelia D
AU  - Razis ED
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor beta)
SB  - IM
MH  - Benzamides
MH  - Chromosome Aberrations
MH  - Dermatofibrosarcoma/diagnostic imaging/*drug therapy/pathology
MH  - Female
MH  - Humans
MH  - Imatinib Mesylate
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Mutation/genetics
MH  - Piperazines/*therapeutic use
MH  - Positron-Emission Tomography
MH  - Pyrimidines/*therapeutic use
MH  - Receptor, Platelet-Derived Growth Factor beta/genetics
MH  - Remission Induction
MH  - Skin Neoplasms/diagnostic imaging/*drug therapy/secondary
EDAT- 2005/03/05 09:00
MHDA- 2005/07/06 09:00
CRDT- 2005/03/05 09:00
PHST- 2005/03/05 09:00 [pubmed]
PHST- 2005/07/06 09:00 [medline]
PHST- 2005/03/05 09:00 [entrez]
AID - 00001813-200504000-00014 [pii]
AID - 10.1097/00001813-200504000-00014 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2005 Apr;16(4):461-6. doi: 10.1097/00001813-200504000-00014.